1 INTRODUCTION

1.1 MARKET DEFINITION

1.2 MARKET SEGMENTATION

1.3 RESEARCH TIMELINES

1.4 ASSUMPTIONS

1.5 LIMITATIONS
2 RESEARCH METHODOLOGY

2.1 DATA MINING

2.2 SECONDARY RESEARCH

2.3 PRIMARY RESEARCH

2.4 SUBJECT MATTER EXPERT ADVICE

2.5 QUALITY CHECK

2.6 FINAL REVIEW

2.7 DATA TRIANGULATION

2.8 BOTTOM-UP APPROACH

2.9 TOP-DOWN APPROACH

2.10 RESEARCH FLOW

2.11 DATA SOURCES
3 EXECUTIVE SUMMARY

3.1 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET OVERVIEW

3.2 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT ESTIMATES AND FORECAST (USD MILLION), 2021-2030

3.3 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT ECOLOGY MAPPING

3.4 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM

3.5 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT ABSOLUTE MARKET OPPORTUNITY

3.6 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET ATTRACTIVENESS ANALYSIS, BY REGION

3.7 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET ATTRACTIVENESS ANALYSIS, BY PRODUCT

3.8 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET ATTRACTIVENESS ANALYSIS, BY SCAR TYPE

3.9 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET ATTRACTIVENESS ANALYSIS, BY END-USE

3.10 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET GEOGRAPHICAL ANALYSIS (CAGR %)

3.11 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY PRODUCT (USD MILLION)

3.12 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY SCAR TYPE (USD MILLION)

3.13 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY END-USE (USD MILLION)

3.14 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY GEOGRAPHY (USD MILLION)

3.15 FUTURE MARKET OPPORTUNITIES
4 MARKET OUTLOOK
4.1 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET EVOLUTION
4.2 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET OUTLOOK
4.3 MARKET DRIVERS

4.3.1 THE IMPORTANCE OF ESTHETIC APPEARANCE IS BEING EMPHASIZED MORE THAN EVER BEFORE

4.3.2 RISING AWARENESS AND COSMETIC CONCERNS
4.4 MARKET RESTRAINTS

4.4.1 HIGH COST OF TREATMENT

4.4.2 LIMITED ACCESS TO SPECIALIZED HEALTHCARE FACILITIES
4.5 MARKET TRENDS

4.5.1 ADVANCEMENTS IN TREATMENT TECHNOLOGIES

4.5.2 DEVELOPMENT OF ADVANCED TOPICAL FORMULATIONS
4.6 MARKET OPPORTUNITY

4.6.1 EMPHASIZING ON PERSONALIZED TREATMENT PLANS

4.6.2 RISING DEMAND FOR AESTHETIC PROCEDURES
4.7 PORTER’S FIVE FORCES ANALYSIS

4.7.1 THREAT OF NEW ENTRANTS (LOW TO MODERATE)

4.7.2 BARGAINING POWER OF SUPPLIERS (MODERATE)

4.7.3 BARGAINING POWER OF BUYERS (MODERATE TO HIGH)

4.7.4 THREAT OF SUBSTITUTES (MODERATE)

4.7.5 COMPETITIVE RIVALRY (MODERATE TO HIGH)
4.8 VALUE CHAIN ANALYSIS
4.9 PRICING ANALYSIS
4.10 MACROECONOMIC ANALYSIS
5 MARKET, BY PRODUCT

5.1 OVERVIEW

5.2 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY PRODUCT

5.3 TOPICAL PRODUCTS

5.4 LASER PRODUCTS

5.5 INJECTABLES

5.6 OTHERS
6 MARKET, BY SCAR TYPE

6.1 OVERVIEW

6.2 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY SCAR TYPE

6.3 HYPERTROPHIC SCARS

6.4 KELOID SCARS
7 MARKET, BY END-USE

7.1 OVERVIEW

7.2 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY END-USE

7.3 CLINICS

7.4 HOSPITALS

7.5 RETAIL PHARMACIES/ECOMMERCE
8 MARKET, BY GEOGRAPHY

8.1 OVERVIEW

8.2 NORTH AMERICA

8.2.1 U.S.

8.2.2 CANADA

8.2.3 MEXICO

8.3 EUROPE

8.3.1 GERMANY

8.3.2 U.K.

8.3.3 FRANCE

8.3.4 ITALY

8.3.5 SPAIN

8.3.6 REST OF EUROPE

8.4 ASIA PACIFIC

8.4.1 CHINA

8.4.2 JAPAN

8.4.3 INDIA

8.4.4 REST OF ASIA PACIFIC

8.5 LATIN AMERICA

8.5.1 BRAZIL

8.5.2 ARGENTINA

8.5.3 REST OF LATIN AMERICA

8.6 MIDDLE EAST AND AFRICA

8.6.1 UAE

8.6.2 SAUDI ARABIA

8.6.3 SOUTH AFRICA

8.6.4 REST OF MIDDLE EAST AND AFRICA
9 COMPETITIVE LANDSCAPE

9.1 OVERVIEW

9.2 KEY DEVELOPMENT

9.3 COMPANY MARKET RANKING ANALYSIS

9.4 COMPANY REGIONAL FOOTPRINT

9.5 COMPANY APPLICATION FOOTPRINT

9.6 ACE MATRIX

9.6.1 ACTIVE

9.6.2 CUTTING EDGE

9.6.3 EMERGING

9.6.4 INNOVATORS
10 COMPANY PROFILES
10.1 SMITH & NEPHEW

10.1.1 COMPANY OVERVIEW

10.1.2 COMPANY INSIGHTS

10.1.3 SEGMENT BREAKDOWN

10.1.4 PRODUCT BENCHMARKING

10.1.5 KEY DEVELOPMENTS

10.1.6 SWOT ANALYSIS

10.1.7 CURRENT FOCUS & STRATEGIES

10.1.8 THREAT FROM COMPETITION
10.2 MERZ PHARMA

10.2.1 COMPANY OVERVIEW

10.2.2 COMPANY INSIGHTS

10.2.3 SEGMENT BREAKDOWN

10.2.4 PRODUCT BENCHMARKING

10.2.5 KEY DEVELOPMENTS

10.2.6 SWOT ANALYSIS

10.2.7 CURRENT FOCUS & STRATEGIES

10.2.8 THREAT FROM COMPETITION
10.3 MOLNLYCKE HEALTH CARE AB

10.3.1 COMPANY OVERVIEW

10.3.2 COMPANY INSIGHTS

10.3.3 SEGMENT BREAKDOWN

10.3.4 PRODUCT BENCHMARKING

10.3.5 KEY DEVELOPMENTS

10.3.6 SWOT ANALYSIS

10.3.7 CURRENT FOCUS & STRATEGIES

10.3.8 THREAT FROM COMPETITION
10.4 CHABAN GROUP (CHABAN MEDICAL LTD)

10.4.1 COMPANY OVERVIEW

10.4.2 COMPANY INSIGHTS

10.4.3 SEGMENT BREAKDOWN

10.4.4 PRODUCT BENCHMARKING

10.4.5 KEY DEVELOPMENTS

10.4.6 SWOT ANALYSIS

10.4.7 CURRENT FOCUS & STRATEGIES

10.4.8 THREAT FROM COMPETITION
10.5 BIODERMIS

10.5.1 COMPANY OVERVIEW

10.5.2 COMPANY INSIGHTS

10.5.3 SEGMENT BREAKDOWN

10.5.4 PRODUCT BENCHMARKING

10.5.5 KEY DEVELOPMENTS

10.5.6 SWOT ANALYSIS

10.5.7 CURRENT FOCUS & STRATEGIES

10.5.8 THREAT FROM COMPETITION
10.6 CYNOSURE

10.6.1 COMPANY OVERVIEW

10.6.2 COMPANY INSIGHTS

10.6.3 SEGMENT BREAKDOWN

10.6.4 PRODUCT BENCHMARKING

10.6.5 KEY DEVELOPMENTS

10.6.6 SWOT ANALYSIS

10.6.7 CURRENT FOCUS & STRATEGIES

10.6.8 THREAT FROM COMPETITION
10.7 SUNEVA MEDICAL INC.

10.7.1 COMPANY OVERVIEW

10.7.2 COMPANY INSIGHTS

10.7.3 SEGMENT BREAKDOWN

10.7.4 PRODUCT BENCHMARKING

10.7.5 KEY DEVELOPMENTS

10.7.6 SWOT ANALYSIS

10.7.7 CURRENT FOCUS & STRATEGIES

10.7.8 THREAT FROM COMPETITION
10.8 SONOMA PHARMACEUTICALS INC

10.8.1 COMPANY OVERVIEW

10.8.2 COMPANY INSIGHTS

10.8.3 SEGMENT BREAKDOWN

10.8.4 PRODUCT BENCHMARKING

10.8.5 KEY DEVELOPMENTS

10.8.6 SWOT ANALYSIS

10.8.7 CURRENT FOCUS & STRATEGIES

10.8.8 THREAT FROM COMPETITION
10.9 LUMENIS BE LTD

10.9.1 COMPANY OVERVIEW

10.9.2 COMPANY INSIGHTS

10.9.3 SEGMENT BREAKDOWN

10.9.4 PRODUCT BENCHMARKING

10.9.5 KEY DEVELOPMENTS

10.9.6 SWOT ANALYSIS

10.9.7 CURRENT FOCUS & STRATEGIES

10.9.8 THREAT FROM COMPETITION
10.10 ALLIANCE PHARMA PLC

10.10.1 COMPANY OVERVIEW

10.10.2 COMPANY INSIGHTS

10.10.3 SEGMENT BREAKDOWN

10.10.4 PRODUCT BENCHMARKING

10.10.5 KEY DEVELOPMENTS

10.10.6 SWOT ANALYSIS

10.10.7 CURRENT FOCUS & STRATEGIES

10.10.8 THREAT FROM COMPETITION
LIST OF TABLES

TABLE 1 PROJECTED REAL GDP GROWTH (ANNUAL PERCENTAGE CHANGE) OF KEY COUNTRIES

TABLE 2 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 3 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY SCAR TYPE, 2022-2031 (USD MILLION)

TABLE 4 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY END-USE, 2022-2031 (USD MILLION)

TABLE 5 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY GEOGRAPHY, 2022-2031 (USD MILLION)

TABLE 6 NORTH AMERICA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 7 NORTH AMERICA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 8 NORTH AMERICA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY SCAR TYPE, 2022-2031 (USD MILLION)

TABLE 9 NORTH AMERICA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY END-USE, 2022-2031 (USD MILLION)

TABLE 10 U.S. HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 11 U.S. HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY SCAR TYPE, 2022-2031 (USD MILLION)

TABLE 12 U.S. HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY END-USE, 2022-2031 (USD MILLION)

TABLE 13 CANADA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 14 CANADA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY SCAR TYPE, 2022-2031 (USD MILLION)

TABLE 15 CANADA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY END-USE, 2022-2031 (USD MILLION)

TABLE 16 MEXICO HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 17 MEXICO HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY SCAR TYPE, 2022-2031 (USD MILLION)

TABLE 18 MEXICO HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY END-USE, 2022-2031 (USD MILLION)

TABLE 19 EUROPE HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 20 EUROPE HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 21 EUROPE HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY SCAR TYPE, 2022-2031 (USD MILLION)

TABLE 22 EUROPE HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY END-USE, 2022-2031 (USD MILLION)

TABLE 23 GERMANY HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 24 GERMANY HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY SCAR TYPE, 2022-2031 (USD MILLION)

TABLE 25 GERMANY HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY END-USE, 2022-2031 (USD MILLION)

TABLE 26 U.K. HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 27 U.K. HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY SCAR TYPE, 2022-2031 (USD MILLION)

TABLE 28 U.K. HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY END-USE, 2022-2031 (USD MILLION)

TABLE 29 FRANCE HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 30 FRANCE HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY SCAR TYPE, 2022-2031 (USD MILLION)

TABLE 31 FRANCE HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY END-USE, 2022-2031 (USD MILLION)

TABLE 32 ITALY HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 33 ITALY HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY SCAR TYPE, 2022-2031 (USD MILLION)

TABLE 34 ITALY HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY END-USE, 2022-2031 (USD MILLION)

TABLE 35 SPAIN HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 36 SPAIN HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY SCAR TYPE, 2022-2031 (USD MILLION)

TABLE 37 SPAIN HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY END-USE, 2022-2031 (USD MILLION)

TABLE 38 REST OF EUROPE HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 39 REST OF EUROPE HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY SCAR TYPE, 2022-2031 (USD MILLION)

TABLE 40 REST OF EUROPE HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY END-USE, 2022-2031 (USD MILLION)

TABLE 41 ASIA PACIFIC HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 42 ASIA PACIFIC HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 43 ASIA PACIFIC HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY SCAR TYPE, 2022-2031 (USD MILLION)

TABLE 44 ASIA PACIFIC HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY END-USE, 2022-2031 (USD MILLION)

TABLE 45 CHINA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 46 CHINA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY SCAR TYPE, 2022-2031 (USD MILLION)

TABLE 47 CHINA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY END-USE, 2022-2031 (USD MILLION)

TABLE 48 JAPAN HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 49 JAPAN HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY SCAR TYPE, 2022-2031 (USD MILLION)

TABLE 50 JAPAN HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY END-USE, 2022-2031 (USD MILLION)

TABLE 51 INDIA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 52 INDIA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY SCAR TYPE, 2022-2031 (USD MILLION)

TABLE 53 INDIA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY END-USE, 2022-2031 (USD MILLION)

TABLE 54 REST OF ASIA PACIFIC HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 55 REST OF ASIA PACIFIC HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY SCAR TYPE, 2022-2031 (USD MILLION)

TABLE 56 REST OF ASIA PACIFIC HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY END-USE, 2022-2031 (USD MILLION)

TABLE 57 LATIN AMERICA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 58 LATIN AMERICA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 59 LATIN AMERICA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY SCAR TYPE, 2022-2031 (USD MILLION)

TABLE 60 LATIN AMERICA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY END-USE, 2022-2031 (USD MILLION)

TABLE 61 BRAZIL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 62 BRAZIL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY SCAR TYPE, 2022-2031 (USD MILLION)

TABLE 63 BRAZIL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY END-USE, 2022-2031 (USD MILLION)

TABLE 64 ARGENTINA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 65 ARGENTINA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY SCAR TYPE, 2022-2031 (USD MILLION)

TABLE 66 ARGENTINA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY END-USE, 2022-2031 (USD MILLION)

TABLE 67 REST OF LATIN AMERICA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 68 REST OF LATIN AMERICA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY SCAR TYPE, 2022-2031 (USD MILLION)

TABLE 69 REST OF LATIN AMERICA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY END-USE, 2022-2031 (USD MILLION)

TABLE 70 MIDDLE EAST AND AFRICA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 71 MIDDLE EAST AND AFRICA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 72 MIDDLE EAST AND AFRICA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY SCAR TYPE, 2022-2031 (USD MILLION)

TABLE 73 MIDDLE EAST AND AFRICA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY END-USE, 2022-2031 (USD MILLION)

TABLE 74 UAE HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 75 UAE HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY SCAR TYPE, 2022-2031 (USD MILLION)

TABLE 76 UAE HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY END-USE, 2022-2031 (USD MILLION)

TABLE 77 SAUDI ARABIA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 78 SAUDI ARABIA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY SCAR TYPE, 2022-2031 (USD MILLION)

TABLE 79 SAUDI ARABIA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY END-USE, 2022-2031 (USD MILLION)

TABLE 80 SOUTH AFRICA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 81 SOUTH AFRICA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY SCAR TYPE, 2022-2031 (USD MILLION)

TABLE 82 SOUTH AFRICA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY END-USE, 2022-2031 (USD MILLION)

TABLE 83 REST OF MIDDLE EAST AND AFRICA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 84 REST OF MIDDLE EAST AND AFRICA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY SCAR TYPE, 2022-2031 (USD MILLION)

TABLE 85 REST OF MIDDLE EAST AND AFRICA HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY END-USE, 2022-2031 (USD MILLION)

TABLE 86 COMPANY MARKET RANKING ANALYSIS

TABLE 87 COMPANY REGIONAL FOOTPRINT

TABLE 88 COMPANY APPLICATION FOOTPRINT

TABLE 89 SMITH & NEPHEW: PRODUCT BENCHMARKING

TABLE 90 SMITH & NEPHEW: KEY DEVELOPMENTS

TABLE 91 MERZ PHARMA: PRODUCT BENCHMARKING

TABLE 92 MERZ PHARMA: KEY DEVELOPMENTS

TABLE 93 MOLNLYCKE HEALTH CARE AB: PRODUCT BENCHMARKING

TABLE 94 MOLNLYCKE HEALTH CARE AB: KEY DEVELOPMENTS

TABLE 95 CHABAN GROUP: PRODUCT BENCHMARKING

TABLE 96 BIODERMIS: PRODUCT BENCHMARKING

TABLE 97 CYNOSURE: PRODUCT BENCHMARKING

TABLE 98 CYNOSURE: KEY DEVELOPMENTS

TABLE 99 SUNEVA MEDICAL INC.: PRODUCT BENCHMARKING

TABLE 100 SUNEVA MEDICAL INC.: KEY DEVELOPMENTS

TABLE 101 SONOMA PHARMACEUTICALS INC: PRODUCT BENCHMARKING

TABLE 102 SONOMA PHARMACEUTICALS INC: KEY DEVELOPMENTS

TABLE 103 LUMENIS BE LTD: PRODUCT BENCHMARKING

TABLE 104 ALLIANCE PHARMA PLC: PRODUCT BENCHMARKING

TABLE 105 ALLIANCE PHARMA PLC: KEY DEVELOPMENTS
LIST OF FIGURES

FIGURE 1 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET SEGMENTATION

FIGURE 2 RESEARCH TIMELINES

FIGURE 3 DATA TRIANGULATION

FIGURE 4 MARKET RESEARCH FLOW

FIGURE 5 DATA SOURCES

FIGURE 6 EXECUTIVE SUMMARY

FIGURE 7 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT ESTIMATES AND FORECAST (USD MILLION), 2021-2030

FIGURE 8 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM

FIGURE 9 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT ABSOLUTE MARKET OPPORTUNITY

FIGURE 10 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET ATTRACTIVENESS ANALYSIS, BY REGION

FIGURE 11 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET ATTRACTIVENESS ANALYSIS, BY PRODUCT

FIGURE 12 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET ATTRACTIVENESS ANALYSIS, BY SCAR TYPE

FIGURE 13 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET ATTRACTIVENESS ANALYSIS, BY END-USE

FIGURE 14 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET GEOGRAPHICAL ANALYSIS, 2024-31

FIGURE 15 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY PRODUCT (USD MILLION)

FIGURE 16 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY SCAR TYPE (USD MILLION)

FIGURE 17 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY END-USE (USD MILLION)

FIGURE 18 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY GEOGRAPHY (USD MILLION)

FIGURE 19 FUTURE MARKET OPPORTUNITIES

FIGURE 20 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET OUTLOOK

FIGURE 21 MARKET DRIVERS_IMPACT ANALYSIS

FIGURE 22 MARKET RESTRAINTS_IMPACT ANALYSIS

FIGURE 23 MARKET TRENDS

FIGURE 24 KEY OPPORTUNITIES_IMPACT ANALYSIS

FIGURE 25 PORTER’S FIVE FORCES ANALYSIS

FIGURE 26 VALUE CHAIN ANALYSIS

FIGURE 27 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY PRODUCT, VALUE SHARES IN 2023

FIGURE 28 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET BASIS POINT SHARE (BPS) ANALYSIS, BY PRODUCT

FIGURE 29 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY SCAR TYPE, VALUE SHARES IN 2023

FIGURE 30 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET BASIS POINT SHARE (BPS) ANALYSIS, BY SCAR TYPE

FIGURE 31 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY END-USE

FIGURE 32 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET BASIS POINT SHARE (BPS) ANALYSIS, BY END-USE

FIGURE 33 GLOBAL HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET, BY GEOGRAPHY, 2022-2031 (USD MILLION)

FIGURE 34 NORTH AMERICA MARKET SNAPSHOT

FIGURE 35 U.S. MARKET SNAPSHOT

FIGURE 36 CANADA MARKET SNAPSHOT

FIGURE 37 MEXICO MARKET SNAPSHOT

FIGURE 38 EUROPE MARKET SNAPSHOT

FIGURE 39 GERMANY MARKET SNAPSHOT

FIGURE 40 U.K. MARKET SNAPSHOT

FIGURE 41 FRANCE MARKET SNAPSHOT

FIGURE 42 ITALY MARKET SNAPSHOT

FIGURE 43 SPAIN MARKET SNAPSHOT

FIGURE 44 REST OF EUROPE MARKET SNAPSHOT

FIGURE 45 ASIA PACIFIC MARKET SNAPSHOT

FIGURE 46 CHINA MARKET SNAPSHOT

FIGURE 47 JAPAN MARKET SNAPSHOT

FIGURE 48 INDIA MARKET SNAPSHOT

FIGURE 49 REST OF ASIA PACIFIC MARKET SNAPSHOT

FIGURE 50 LATIN AMERICA MARKET SNAPSHOT

FIGURE 51 BRAZIL MARKET SNAPSHOT

FIGURE 52 ARGENTINA MARKET SNAPSHOT

FIGURE 53 REST OF LATIN AMERICA MARKET SNAPSHOT

FIGURE 54 MIDDLE EAST AND AFRICA MARKET SNAPSHOT

FIGURE 55 UAE MARKET SNAPSHOT

FIGURE 56 SAUDI ARABIA MARKET SNAPSHOT

FIGURE 57 SOUTH AFRICA MARKET SNAPSHOT

FIGURE 58 REST OF MIDDLE EAST AND AFRICA MARKET SNAPSHOT

FIGURE 59 KEY STRATEGIC DEVELOPMENTS

FIGURE 60 ACE MATRIX

FIGURE 61 SMITH & NEPHEW: COMPANY INSIGHT

FIGURE 62 SMITH & NEPHEW: SEGMENT BREAKDOWN

FIGURE 63 MERZ PHARMA: COMPANY INSIGHT

FIGURE 64 MOLNLYCKE HEALTH CARE AB.: COMPANY INSIGHT

FIGURE 65 CHABAN MEDICAL LTD: COMPANY INSIGHT

FIGURE 66 BIODERMIS: COMPANY INSIGHT

FIGURE 67 CYNOSURE: COMPANY INSIGHT

FIGURE 68 SUNEVA MEDICAL INC.: COMPANY INSIGHT

FIGURE 69 SONOMA PHARMACEUTICALS INC: COMPANY INSIGHT

FIGURE 70 SONOMA PHARMACEUTICALS INC: SEGMENT BREAKDOWN

FIGURE 71 LUMENIS BE LTD: COMPANY INSIGHT

FIGURE 72 ALLIANCE PHARMA PLC: COMPANY INSIGHT

FIGURE 73 ALLIANCE PHARMA PLC: SEGMENT BREAKDOWN

The research starts with the extensive procurement process of data/information and statistics from company annual reports, government websites, statistics agencies, and paid databases. This information creates a base for the study. The information also helps to define the scope and to narrow down the area for study for the market. This raw information is processed and analyzed to extract crisp data points which currently affect or are likely to affect the industry during the forecast period. After analyzing the information, a proprietary statistical tool is used for market estimation and forecast, which generates the quantitative figures of the market/sub-segments in the current scenario as well as for the forecast period. 

After estimating the markets and estimates, the numbers are verified with industry participants and key opinion leaders. The wide network of industry participants add value to the research and verify the numbers and estimates provided in the study. At the last stage of the research process, a final report is prepared, which is then published on different websites as well as distributed through various channels. The below figure contains the different stages of the research process to produce the report.

1.1 DATA MINING
Data mining is an extensive part of our research process. It involves the procurement of market data and related information from different verified and credible sources. This step helps to obtain raw information about the industry and their Drivetrain, the monetary process for different end uses, the pool of market participants, and the nature of the industry and scope of the study. The data mining stage comprises both primary and secondary sources of information.
1.2 SECONDARY RESEARCH
In the secondary research process, various sources are used to identify and gather industry trends and information for the research process. We at TRI have access to some of the most diversified and extensive paid databases, which give us the most accurate data/information on markets Customers, and pricing. Mentioned below is a detailed list of sources that have been used for this study. Please note that this list is not limited to the names as mentioned; we also access other data sources depending on the need.
1.3 PRIMARY RESEARCH
In the primary research process, in-depth primary interviews are conducted with the CXOs to understand the market share, customer base, pricing strategies, channel partners, and other necessary information. Besides, in-depth primary interviews are conducted with the CXOs of vendors, channel partners, and others to validate the supply-side information. In addition, various key industry participants from both the supply and demand side are interviewed to obtain qualitative and quantitative information on the market. In-depth interviews with key primary respondents, including industry professionals, subject matter experts (Corporates), industry consultants, and C-Component executives of major companies, are conducted to obtain critical qualitative and quantitative information pertaining to the market, as well as to assess the prospects for market growth during the forecast period. Detailed information on these primary respondents is mentioned below. 
1.4 FORCASTING TECHNIQUES
We at Markstats Research Insights Private Limited follow an extensive process for arriving at market estimations, which involves the use of multiple forecasting techniques as mentioned below.